title: Novel strategies for the treatment of inflammatory bowel disease: Selective inhibition of cytokines and adhesion molecules.
abstract: The etiology of inflammatory bowel disease (IBD) has not yet been clarified and immunosuppressive agents which non-specifically reduce inflammation and immunity have been used in the conventional therapies for IBD. Evidence indicates that a dysregulation of mucosal immunity in the gut of IBD causes an overproduction of inflammatory cytokines and trafficking of effector leukocytes into the bowel, thus leading to an uncontrolled intestinal inflammation. Such recent advances in the understanding of the pathogenesis of IBD created a recent trend of novel biological therapies which specifically inhibit the molecules involved in the inflammatory cascade. Major targets for such treatment are inflammatory cytokines and their receptors, and adhesion molecules. A chimeric anti-TNF-alpha monoclonal antibody, infliximab, has become a standard therapy for CD and it is also likely to be beneficial for UC. Several anti-TNF reagents have been developed but most of them seem to not be as efficacious as infliximab. A humanized anti-TNF monoclonal antibody, adalimumab may be useful for the treatment of patients who lost responsiveness or developed intolerance to infliximab. Antibodies against IL-12 p40 and IL-6 receptor could be alternative new anti-cytokine therapies for IBD. Anti-interferon-gamma and anti-CD25 therapies were developed, but the benefit of these agents has not yet been established. The selective blocking of migration of leukocytes into intestine seems to be a nice approach. Antibodies against alpha4 integrin and alpha4beta7 integrin showed benefit for IBD. Antisense oligonucleotide of intercellular adhesion molecule 1 (ICAM-1) may be efficacious for IBD. Clinical trials of such compounds have been either recently reported or are currently underway. In this article, we review the efficacy and safety of such novel biological therapies for IBD.
authors.affiliation: Fukuoka-Higashi Medical Center, 1-1-1, Chidori, Koga-city, Fukuoka 811-3195, Japan.
authors.forename: Kazuhiko
authors.initials: K
authors.lastname: Nakamura
authors.forename: Kuniomi
authors.initials: K
authors.lastname: Honda
authors.forename: Takahiro
authors.initials: T
authors.lastname: Mizutani
authors.forename: Hirotada
authors.initials: H
authors.lastname: Akiho
authors.forename: Naohiko
authors.initials: N
authors.lastname: Harada
mesh_terms: D000818:Animals; D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D015815:Cell Adhesion Molecules / Q000037:antagonists & inhibitors*; D002465:Cell Movement / Q000187:drug effects; D002986:Clinical Trials as Topic; D016207:Cytokines / Q000037:antagonists & inhibitors*; D005765:Gastrointestinal Agents / Q000627:therapeutic use; D006801:Humans; D015212:Inflammatory Bowel Diseases / Q000188:drug therapy*; D000069285:Infliximab; D016376:Oligonucleotides, Antisense / Q000627:therapeutic use; D018121:Receptors, Cytokine / Q000037:antagonists & inhibitors; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors
chemical_list: D000911:Antibodies, Monoclonal; D015815:Cell Adhesion Molecules; D016207:Cytokines; D005765:Gastrointestinal Agents; D016376:Oligonucleotides, Antisense; D018121:Receptors, Cytokine; D014409:Tumor Necrosis Factor-alpha; D000069285:Infliximab